Based on: Migraine — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 47 candidate interventions for migraine that are either approved medicines or have at least one registered clinical trial, built on 9 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 9 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Dihydroergotamine — 3 registered trials · approved medicine · NCT05337254
- Frovatriptan — 2 registered trials · approved medicine · NCT00644033
- Rimegepant — 2 registered trials · approved medicine · NCT06439628 NCT03237845
- PRT-064040 nasal spray — 2 registered trials · investigational · NCT07016516
- almotriptan malate — 1 registered trial · approved medicine · NCT00210509
- Botulinum toxin type A — 1 registered trial · approved medicine · NCT03381261
- Eptinezumab — 1 registered trial · approved medicine · NCT07035197
- Fremanezumab — 1 registered trial · approved medicine · NCT04464707
- Galcanezumab — 1 registered trial · approved medicine · NCT02163993
- topiramate — 1 registered trial · approved medicine · NCT00210873
- Active drug for chronic migraine treatment. — 1 registered trial · investigational · NCT07071506
- AMG334 — 1 registered trial · investigational · NCT03927144
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in migraine and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: CACNA1A, CALCA, CALCRL, HTR1B, HTR1D, HTR1F, NOS3, RAMP1, TRPV1.
Which trials are registered?
- Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) NCT07347028 · Recruiting · Phase NA · started 2025-10-01
- Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy NCT07629635 · Recruiting · Phase PHASE3 · started 2026-10-15
- Greater Occipital Nerve Block for Migraine With Medication Overuse Headache NCT07568496 · Recruiting · Phase NA · started 2026-05-12
- RELAXaHEAD for Headache Patients (Phase III) NCT06077838 · Recruiting · Phase NA · started 2023-11-08
- Family Study of Affective and Anxiety Spectrum Disorders NCT00071786 · Completed · started 2004-05-21
- NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder NCT05669703 · Recruiting · started 2023-11-03
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine NCT07816367 · Recruiting · Phase PHASE3 · started 2026-10-02
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine NCT05711394 · Recruiting · Phase PHASE3 · started 2023-05-01
- Study of EVO756 in Adults With Migraine NCT07616128 · Recruiting · Phase PHASE2 · started 2026-07-29
- Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment NCT07361549 · Recruiting · Phase PHASE2 · started 2026-09-09
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.